Sana Biotechnology Inc (SANA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| CEO: | Steven D. Harr |
| Employees: | 380 |
| Web site: | sana.com |
|
188 EAST BLAINE STREET, SUITE 400, SEATTLE, WA, 98102
(206) 701-7914
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.